Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, ≥ 18 years of age
Rheumatoid arthritis of ≥ 6 months duration, diagnosed according to the revised 1987 American College of Rheumatology criteria
Inadequate response to at least one approved anti-TNF agent (adalimumab, etanercept, infliximab, golimumab, or certolizumab)
Patients who have received 1 to 2 prior courses of rituximab (RTX) may be enrolled, provided their most recent course of RTX occurred over 6 months but no more than 9 months prior to baseline. The RTX dosage must have been two 1000 mg infusions per course administered at the standard approved rate
Methotrexate treatment between 10 and 25 mg/week (oral or parenteral) for at least 8 weeks immediately prior to baseline
You may not be if
Major surgery (including joint surgery) within 8 weeks prior to screening or planned surgery within 6 months following baseline
Rheumatic autoimmune disease other than rheumatoid arthritis
Functional class IV as defined by American College of Rheumatology (ACR) criteria
Prior history of or current inflammatory joint disease other than rheumatoid arthritis
History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies
Previous serious infusion reaction to any prior biologic therapy
Known active current or history of recurrent infection
